{
  "abstract": "Introduction The BSG IBD surveillance guideline update includes an advanced colorectal neoplasia (aCRN) risk assessment tool 1,2 (aCRN RAT), a dynamic evidence-based prediction model to determine personalised 5-year aCRN risk to inform surveillance interval. At Oxford University Hospitals NHS Trust, aCRN RAT has been incorporated into IBD surveillance assessment.Methods A retrospective cohort study was conducted, evaluating electronic records of patients who underwent surveillance colonoscopy at OUH NHS Trust from July-August 2025. MDT determined surveillance intervals were compared with strict application of aCRN RAT in all eligible cases, and the alternative approach of ascribing single risk factors to surveillance intervals, also endorsed by current BSG 2 and ECCO3 malignancy guidance (herein termed BSG 2025 boxes and ECCO 2023 boxes).Results 61 (F:M = 30:31) patients underwent IBD surveillance colonoscopy. Median (IQR) age was 47.1(36.2-62.2) years. All patients had colonic IBD (CD:UC:IBD-PSC = 8:43:10). 47 patients fulfilled eligibility criteria for use of aCRN RAT, with median 5-year aCRN risk of 1.1(0.5-1.5)%. 1 case of multifocal LGD was detected, with patient counselled for colectomy. Surveillance intervals as determined by OUH surveillance MDT with IBD clinician patient specific input, exclusive use of aCRN RAT when patient eligible, BSG 2025 boxes or ECCO 2023 boxes are summarised in figure 1. Deviations between OUH MDT outcome and aCRN RAT informed surveillance intervals involved cases of PSC or young age, with concerns regarding cumulative risk.Conclusion The incorporation of aCRN RAT into determination of surveillance intervals significantly reduces need for future colonoscopy. When this model is used, care must be taken to re-evaluate patients following subsequent disease flares, given the dynamic nature of risk.References https://ibd-dysplasia-calculator.bmrc.ox.ac.uk/East JE, et al. BSG IBD surveillance guidelines 2025.Gordon H, et al. ECCO IBD malignancy guideline 2023.Abstract P190 Figure 1A) surveillance intervals as determined by OUH surveillance MDT outcome, aCRN RAT, BSG 2025 and ECCO malignancy 2023 guideline; B) use of advanced colorectal neoplasia risk assessment tool reduces need for future surveillance colonoscopy",
  "authors": [
    {
      "affiliations": [
        "Translational Gastroenterology and Liver Unit, John Radcliffe Hospital, United Kingdom"
      ],
      "name": "Alice Gant"
    },
    {
      "affiliations": [
        "Translational Gastroenterology and Liver Unit, John Radcliffe Hospital, United Kingdom"
      ],
      "name": "Amy Warwick"
    },
    {
      "affiliations": [
        "Translational Gastroenterology and Liver Unit, John Radcliffe Hospital, United Kingdom"
      ],
      "name": "Lydia White"
    },
    {
      "affiliations": [
        "Translational Gastroenterology and Liver Unit, John Radcliffe Hospital, United Kingdom"
      ],
      "name": "Oliver Brain"
    },
    {
      "affiliations": [
        "Translational Gastroenterology and Liver Unit, John Radcliffe Hospital, United Kingdom"
      ],
      "name": "Alissa Walsh"
    },
    {
      "affiliations": [
        "Translational Gastroenterology and Liver Unit, John Radcliffe Hospital, United Kingdom"
      ],
      "name": "James E East"
    },
    {
      "affiliations": [
        "Translational Gastroenterology and Liver Unit, John Radcliffe Hospital, United Kingdom"
      ],
      "name": "Vincent Cheung"
    },
    {
      "affiliations": [
        "Translational Gastroenterology and Liver Unit, John Radcliffe Hospital, United Kingdom"
      ],
      "name": "Hannah Gordon"
    }
  ],
  "title": "P190 The BSG IBD surveillance guideline endorsed advanced colorectal neoplasia risk assessment tool significantly reduces the need for future surveillance colonoscopy",
  "uid": "f06d738c-1274-5429-8935-f1d2c0dfa1b2"
}